Revolution Medicines, Inc. (RVMD) Earnings

Revolution Medicines, Inc.

RVMD · NASDAQ-GS

Jun 2026upcoming

Next quarter

Consensus is -$1.93 EPS for Jun 2026 across 9 estimates, ranging -$2.34 to -$0.85.

RVMD Mar 2026

Reported May 6, 2026

Miss 25.14%

EPS estimate: -$1.83
EPS actual: -$2.29
Revenue estimate: —
Revenue actual: —
1-day move: -5.67%

Call highlights have not been generated for this quarter.

Symbol: RVMD
Type: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
Country: North America
Exchange: NASDAQ-GS

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company's pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).

Key Issues

Bullish view

Revolution Medicines has a promising cancer drug in development, and the stock has attracted favorable coverage and a 13-analyst Buy consensus. Those signals support the view that future clinical and commercial potential can underpin the valuation.

Bearish view

The company reports no revenue and lost $1.1 billion in FY2025. Until the development program produces commercial evidence, the valuation rests on an unmarketed asset and carries substantial execution risk.

Analyst Consensus

See all

Buy

13 analysts

$197

Current

—

Low

$210

Average

—

High

Average target implies +6.83% versus the current price.

Earnings History

BeatMissNo estimate

Peers

IDEXX Laboratories, Inc.IDXX · NASDAQ-GS